Efficacy of sleeve lobectomy after neoadjuvant chemoimmunotherapy in lung cancer: A retrospective cohort study
- VernacularTitle:新辅助免疫治疗联合化疗后袖式切除术治疗肺癌的回顾性队列研究
- Author:
Zheng WANG
1
;
Meng WANG
1
;
Daqiang SUN
1
Author Information
1. Department of Thoracic Surgery, Tianjin Chest Hospital Affiliated to Tianjin University, Tianjin, 300222, P. R. China
- Publication Type:Journal Article
- Keywords:
Lung cancer;
sleeve lobectomy;
neoadjuvant immunochemotherapy
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2024;31(12):1775-1780
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the outcomes of sleeve resection following neoadjuvant chemoimmunotherapy for lung cancer. Methods The clinical data of patients diagnosed with lung cancer and underwent sleeve lobectomy surgery at Tianjin Chest Hospital were retrospectively analyzed. Patients were divided into two groups: a neoadjuvant treatment group and a surgery alone group. The clinical data of two groups were compared. Results Finally 22 patients were collected, including 19 males and 3 females with a median age of 63 years. There were 7 patients in the neoadjuvant treatment group, and 15 patients in the surgery alone group. There was no statistical difference in surgical time, intraoperative bleeding, lymph node dissection, postoperative catheterization time, or postoperative drainage volume between the two groups (P>0.05). In the neoadjuvant treatment group, 1 patient had a second thoracotomy exploration for hemostasis due to bronchial artery bleeding, 2 patients had wound infection, 1 patient had immune-associated pneumonia before surgery, and 1 patient had immune-associated pneumonia before postoperative adjuvant therapy. Postoperative pathological results of patients in the neoadjuvant treatment group showed that 1 (1/7, 14.3%) patient had pathological complete response, and 3 (3/7, 42.9%) patients achieved major pathological response. Conclusion Neoadjuvant chemoimmunotherapy can lead to complications, including operation-related complications and immunotherapy-related complications. However, the degree of postoperative pathological remission is also significantly improved. Overall, sleeve resection following neoadjuvant chemoimmunotherapy can be considered as a treatment option for patients with lung cancer.
